Thank you for subscribing!
Next Investors Archived Oct 26, 2016
Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.
Finfeed Archived Oct 06, 2016
Shares in Cellmid (ASX: CDY) were up approximately 30% at one stage on Wednesday after the company released promising results regarding the preclinical collaborative trials being undertaken in relation to its anti-midkine antibodies (MK antibodies).
Finfeed Archived Aug 24, 2016
Monday’s announcement of Pfizer Inc’s acquisition of NASDAQ listed Medivation for $14 billion created plenty of attention in the health and biotech space.
Finfeed Archived Aug 22, 2016
Noxopharm (ASX:NOX) will move into radiotherapy in addition to chemotherapy – a move CEO Graham Kelly calls an “extraordinary and unique market opportunity”.
Get expert stock analysis direct in your inbox
Finfeed Archived Aug 10, 2016
Noxopharm (ASX:NOX) has confirmed it is on track to start clinical trials of its lead cancer drug, NOX66, in Europe by the end of the year.
Next Investors Archived Aug 09, 2016
The weird and wonderful world of Biotechnology has a lot going for it — an industry working at the sharp-end of breakthrough medical research, Biotech is also one of the more enticing investment landscapes of modern times. In how many other industries are companies literally striving to save lives?
Next Investors Archived Jul 19, 2016
One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.
Next Investors Archived Jun 23, 2016
This ASX micro cap stock has not just one but three potentially winning plays. The company, with a market cap of under $1.5M, has interests in two biotech entities, and also has a stake in a high potential offshore oil and gas play with a key exploration event on the horizon.
Next Investors Archived Jun 14, 2016
With a total global market of $90 billion, successful hair loss products can generate hundreds of millions of dollars in revenue. However the current market leaders may soon be under pressure from one particular ASX listed life sciences company.
Join Our Mailing List
